pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AdCom · news · pharmadog
← back to AdCom
News · AdCom
209
stories
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 21, 26
Capricor investor calls for change as company awaits decision on Duchenne candidate
biospace
Aug 20, 26
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
Aug 19, 26
Trump picks White House aide Heidi Overton as FDA chief: Reports
biospace
Aug 19, 26
Physician group sues Trump administration over dietary guidelines process
stat
Aug 14, 26
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
endpoints
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
Aug 14, 26
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
Aug 12, 26
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
Aug 10, 26
STAT+: FDA panel to weigh Grail’s Galleri test
stat
Aug 7, 26
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial
endpoints
Aug 7, 26
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
STAT+: FDA approves Replimune melanoma drug previously rejected twice
stat
Aug 6, 26
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 6, 26
Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
stat
Aug 6, 26
Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
biospace
Aug 6, 26
FDA approves Moderna’s mRNA flu vaccine
biopharma dive
Aug 6, 26
FDA approves Moderna’s mRNA flu vaccine, the first to use the technology
stat
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Jul 31, 26
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
Jul 31, 26
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
Jul 31, 26
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
stat
Jul 31, 26
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
Jul 31, 26
This Week at FDA: ‘Simple reform’ reorg, adcomm updates, and more
raps
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
Replimune scores win as FDA advisors back melanoma treatment
endpoints
Jul 30, 26
Capricor’s data clash and a fugitive in the C-suite
stat
Jul 30, 26
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
← prev
page 4 of 7
next →